Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report

Linear IgA/IgG bullous dermatosis (LAGBD) is a rare, autoimmune blistering skin disease. We report a case of LAGBD in a 70‐year‐old woman. All common treatments were discontinued due to side effects or lack of treatment response. The patient was successfully treated with omalizumab which cleared her...

Descripción completa

Detalles Bibliográficos
Autores principales: Haulrig, Morten Bahrt, Nielsen, Signe Ledou, Elberling, Jesper, Skov, Lone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905130/
https://www.ncbi.nlm.nih.gov/pubmed/35280104
http://dx.doi.org/10.1002/ccr3.5368
_version_ 1784665122791227392
author Haulrig, Morten Bahrt
Nielsen, Signe Ledou
Elberling, Jesper
Skov, Lone
author_facet Haulrig, Morten Bahrt
Nielsen, Signe Ledou
Elberling, Jesper
Skov, Lone
author_sort Haulrig, Morten Bahrt
collection PubMed
description Linear IgA/IgG bullous dermatosis (LAGBD) is a rare, autoimmune blistering skin disease. We report a case of LAGBD in a 70‐year‐old woman. All common treatments were discontinued due to side effects or lack of treatment response. The patient was successfully treated with omalizumab which cleared her lesions after three months.
format Online
Article
Text
id pubmed-8905130
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89051302022-03-10 Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report Haulrig, Morten Bahrt Nielsen, Signe Ledou Elberling, Jesper Skov, Lone Clin Case Rep Case Reports Linear IgA/IgG bullous dermatosis (LAGBD) is a rare, autoimmune blistering skin disease. We report a case of LAGBD in a 70‐year‐old woman. All common treatments were discontinued due to side effects or lack of treatment response. The patient was successfully treated with omalizumab which cleared her lesions after three months. John Wiley and Sons Inc. 2022-03-08 /pmc/articles/PMC8905130/ /pubmed/35280104 http://dx.doi.org/10.1002/ccr3.5368 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Haulrig, Morten Bahrt
Nielsen, Signe Ledou
Elberling, Jesper
Skov, Lone
Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report
title Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report
title_full Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report
title_fullStr Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report
title_full_unstemmed Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report
title_short Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report
title_sort linear iga/igg bullous dermatosis successfully treated with omalizumab: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905130/
https://www.ncbi.nlm.nih.gov/pubmed/35280104
http://dx.doi.org/10.1002/ccr3.5368
work_keys_str_mv AT haulrigmortenbahrt linearigaiggbullousdermatosissuccessfullytreatedwithomalizumabacasereport
AT nielsensigneledou linearigaiggbullousdermatosissuccessfullytreatedwithomalizumabacasereport
AT elberlingjesper linearigaiggbullousdermatosissuccessfullytreatedwithomalizumabacasereport
AT skovlone linearigaiggbullousdermatosissuccessfullytreatedwithomalizumabacasereport

Ejemplares similares